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A B S T R A C T
Kisspeptin, a hypothalamic neuropeptide, is a member of the RF-amide family, which have been known to
modify pain sensitivity in rodents. The aim of the present study was to investigate the effect of kisspeptin-13 (KP-
13), an endogenous derivative of kisspeptin, on nociception in adult male and female CFLP mice and the possible
interaction of KP-13 with morphine on nociception.
Mice were injected with different doses of KP-13, 30, 60 and 120min after of which the nociceptive sensi-
tivity were assessed via the tail-flick test. To investigate the receptor involved in the mediation a kisspeptin
receptor antagonist (KP-234) pretreatment was applied before KP-13 administration. Furthermore, we in-
vestigated the effect of KP-13 on the acute antinociceptive effect of morphine, on acute morphine tolerance and
on naloxone-precipitated withdrawal. Last, the Von Frey test was used in order to assess KP-13′s effect on
mechanical nociception.
Our results showed that KP-13 decreased the nociceptive threshold of both males and females independent of
sex, which was prevented by KP-234. Furthermore, KP-13 treatment depressed the acute antinociceptive effect of
morphine and attenuated the development of morphine tolerance. KP-13 also induced a mechanical hy-
persensitivity. These data underlie kisspeptin's hyperalgesic action and argues for the role of kisspeptin receptor
1 in the mediation of its action. Furthermore, our results suggest that central KP-13 administration can modify
the acute effects of morphine.
1. Introduction
Kisspeptin, a member of the Arg-Phe (RF)-amide family [38], is a C-
terminally amidated neurohormone and is one of the key regulators of
the hypothalamic-pituitary-gonadal (HPG) axis [43]. The other mem-
bers of the RF-amide family are neuropeptide FF (NPFF) and AF
(NPAF), prolactin releasing peptide (PrRP), RFamide-related peptides,
and the most recently found, pyroglutamylated RFamide peptide [38].
They all share an N-terminal sequence homology and are widely dis-
tributed throughout the central nervous system (CNS); however, they
vary in their structure and receptor preference binding to either one or
several G-protein coupled receptors [2,38].
Kisspeptin, itself, was first isolated from the human placenta as the
endogenous ligand of the orphan G-protein coupled receptor GPR54,
later designated as Kisspeptin receptor 1 (KISS1R) [16,34]. Kisspeptin is
a 54 amino acid long product of the KiSS-1 gene; however, alternative
splicing can give rise to biologically active derivatives containing 14, 13
or 10 aminoacids, named kisspeptin-14 (KP-14), kisspeptin-13 (KP-13)
and kisspeptin-10 (KP-10), respectively [16]. Kisspeptin and its re-
ceptor are abundant in the CNS, especially in the limbic system, the
striatum, the pituitary gland and the hypothalamus [15,34].
The first biological action of kisspeptin was the suppression of
metastasis in melanoma [20], but later, multiple studies demonstrated
the pivotal role of the kisspeptin system in the regulation of the re-
productive axis [43]. Kisspeptin is necessary for the normal secretion of
the gonadotropin releasing hormone (GnRH) [9,42] as well as the lu-
teinizing hormone (LH) and the follicle-stimulating hormone (FSH)
[42,43]. Meanwhile, it may also control the onset of puberty [9]
through its activity on the biological clock of the CNS [45].
Kisspeptin is a member of the RF-amide family that has been pre-
viously implicated in nociception control [38]. Accumulating evidence
strongly suggests a role for the RF-amide family in nociceptive me-
chanism. NPFF and analogues were found to have analgesic, pronoci-
ceptive, and morphine modulating activities [38]. Although initially
described as a solely anti-opioid system, evidence proved otherwise and
now it is believed that the nature of the pharmacology depends on the
subtype targeted, route of administration, and opioid activity [18]. In
point of fact, intracerebroventricular (icv.) administration of NPFF in-
hibits opioid-induced antinociception [11], whereas intrathecal injec-
tion results in the opposite [37]. Both in vitro and in vivo
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pharmacological data suggest that these effects are mediated by the
activation of NPFF receptor 1 and 2 (NPFF1R and NPFF2R) [18], re-
spectively. Distribution data indicates that NPFF2R is found most
abundantly in the spinal cord, whereas in the brain, both receptors are
highly expressed, especially NPFF1R [2]. Recent evidence suggests that
all endogenous RF-amide peptides not only target their cognate re-
ceptors, but also the NPFF1R and NPFF2R receptors, which raises the
idea that all may take a part in pain modulation [10]. It is proposed that
the Arg-Phe-NH2 motif is sufficient for binding with high affinity to
both NPFF receptors [10].
Although much evidence has accumulated in the past couple of
years that ascribes a critical role for the NPFF1R and NPFF2R receptors
for the pain-modulating effects of RF-amide peptides; however, recent
distribution data draws attention to other receptors, such as KISS1R and
GPR10, and their endogenous ligands that are expressed in several
brain areas involved in the control of pain [19]. For instance, both
KISS1R and kisspeptin mRNAs and proteins have been detected in the
dorsal horn of the spinal cord and in the dorsal root ganglia in rats [29].
They have also been detected in brain regions associated with pain
processing (paraventricular thalamic nucleus, periaqueductal gray,
amygdala and locus coeruleus) [6]. Furthermore, kisspeptin has already
been implicated in nociception: intraplantar and intrathecal injection of
kisspeptin-54 evoked hyperalgesia in the formalin test [46], and in-
tracerebroventricular (icv.) kisspeptin-10 also caused a decrease in
nociceptive threshold in the tail immersion test [10]. All of this data
point towards the kisspeptin system’s involvement in nociceptive con-
trol.
Moreover, numerous articles have reported sex differences in pain
sensitivity, responsiveness to pharmacological and non-pharmacolo-
gical pain interventions, the cause of which is unclear as of yet [32].
Emerging evidence indicates the reproductive system and the role of sex
hormones in the regulation of pain sensitivity [1]. Therefore, in the
present study, we first investigated the effect of kisspeptin-13 (KP-13),
an endogenous derivative of kisspeptin, on nociception in adult male
and female CFLP mice to address if KP-13 retains pronociceptive effect
in the tail-flick test and if there’s a difference in KP-13′s effect between
sexes. Secondly, after establishing KP-13′s pronociceptive action, we set
out to assess the possible interaction of KP-13 with the acute effects of
morphine on nociception and the potential involvement of KP-13 in
acute morphine tolerance and withdrawal. Furthermore, with KISS1R
antagonist pretreatment, we wished to illuminate the receptor re-
sponsible for kisspeptin’s actions. Finally, to further characterize KP-
13′s pronociceptive effect we investigated if KP-13 influences me-
chanical sensitivity in the Von Frey test.
2. Materials and methods
2.1. Animals
Female and male adult CFLP white mice (30 ± 5 g of weight) of an
outbred strain (Domaszék, Hungary) were used. They were kept under a
standard light–dark cycle (lights on between 07.00 and 19.00 h) with
food and water available ad libitum. The animals were kept and treated
according to the rules of the Ethical Committee for the Protection of
Animals in Research (Faculty of Medicine, University of Szeged,
Hungary).
2.2. Surgery
For icv. cannulation, the mice were anesthetized with an in-
traperitoneal (ip.) injection of Sodium Pentobarbital (Euthasol,
Phylaxia-Sanofi, Budapest, Hungary; 50 mg/kg). A polyethylene can-
nula was inserted stereotaxically into the right lateral cerebral ventricle
at the coordinates of 0.2mm posterior, 0.2 mm lateral to the bregma
and 2mm deep from dura surface and then cemented to the skull with
cyanoacrylate-containing instant glue. The experiments were started
4 days after icv. cannulation. Upon conclusion of the experiments, 10 μl
of methylene blue were injected into the cerebral ventricle of the de-
capitated animals and the position of the cannula was inspected vi-
sually. The spread of methylene blue throughout the ventricular space
indicated that the whole amount of KP-13 got into the ventricles. Mice
with improper cannula placement were excluded from the final statis-
tical analysis.
2.3. Treatments
Mice were injected with different doses of KP-13 (human, Bachem
Ltd., Switzerland) icv. in a volume of 2 μl over 30 s with a Hamilton
microsyringe, immobilization of the animals being avoided during
handling. The doses applied were 0.5, 1, or 2 μg (0.307, 0.615, and
1.229 nmol, respectively) dissolved in 0.9% saline. For experiments
testing the effect of morphine, subcutaneous (sc.) morphine–HCl
(Sigma-Aldrich Co., USA) and naloxone–HCl (Sigma-Aldrich Co., USA)
injections were used. Kisspeptin-234 (KISS1R antagonist; KP-234)
(Sigma-Aldrich Co., USA) was injected in 0.1 μg (0.077 nmol) dose icv.
The doses selected were based on dose-response studies conducted in
our lab previously that did not affect nociceptive sensitivity per se.
Control animals received saline alone.
2.4. Tail-flick test
The nociceptive sensitivity was tested by the heat-radiant tail-flick
system (IITC Life Science, California, USA) described by [8]. All ex-
periments were started with an initial tail-flick latency measurement,
then nociceptive threshold was measured 30, 60, and 120min after
peptide challenge. For tail-flick measurement, animals were habituated
to the experimental room at least 30min prior to testing. During the
measurement, they were loosely restrained and the tail was positioned
so that the light beam focused on the tail approximately 1–2 cm from
the base. Tail stimulation was delivered after the tail skin of the mice
was preheated to 36 °C and was performed at different sites in con-
secutive measures to prevent tissue damage. The antinociceptive effect
was expressed according to the following equation:
analgesic effect (%)= (TFn− TF0)/TFmax− TF0)× 100
where TF0 is the tail-flick latency in the preliminary test mentioned
above or (in tolerance studies) before morphine injection. TFn is the
value of a repeated corresponding measurement n after KP-13 or/and
morphine injection, and TFmax indicates the cutoff (20 s).
2.5. Manual Von Frey test
The manual Von Frey test was performed to assess the paw with-
drawal thresholds to tactile stimulation [5]. For the manual Von Frey
measurement, animals were habituated to the experimental room at
least 60min prior to testing. Paw withdrawal thresholds (PWTs) of the
right hind paws of the mice were determined in response to probing
with eight calibrated von Frey filaments (Somedic Sales AB, Hörby,
Sweden). The logarithmically spaced increments range from 0.27 to
6.2 g. Each filament was applied perpendicularly to the plantar surface
of the paw of CFLP mice kept in suspended wire-mesh cages. PWT was
determined in grams by the up-down Von Frey method. Mean 50% paw
withdrawal thresholds were calculated by the following equation: PWT
(g)= 10(X+kd)/10000, where X is the final Von Frey filament used (in
log units), k is the tabular value of the response pattern, d mean dif-
ference between stimuli (in log units) (d= 0.269). After the pre-
liminary measurement, the effect of KP-13 on nociceptive sensitivity
was recorded 30, 60 and 120min after peptide administration in male
mice.
The following experiments were carried out:
First, the effect of KP-13 on nociceptive sensitivity was measured
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30, 60 and 120min after peptide administration in both female and
male mice.
Second, the effect of KP-234 on KP-13 induced pronociception was
investigated, in which animals received 0.1 μg dose of KP-234 icv.
followed by KP-13 treatment 30min later. 30, 60 and 120min later tail-
flick latency was assessed.
Third, in experiments with KP-13 on the acute antinociceptive effect
of a single dose of morphine, the peptide was administered 30min prior
to the test dose of morphine (2.4 mg/kg sc.) and the nociceptive
threshold was measured 30 and 60min later.
Fourth, in acute tolerance studies, animals were pretreated with KP-
13 and 60min later, a tolerance-inducing dose of morphine (60mg/kg
sc.) was administered, 24 h after of which a test dose of morphine
(4mg/kg sc.) was injected to assess the antinociceptive effect.
Fifth, in acute withdrawal studies, 30min after KP-13 pretreatment
a tolerance-inducing dose of morphine (60mg/kg) was administered,
3 h after morphine injection animals received naloxone to precipitate
withdrawal signs. The precipitated abstinence syndrome was assessed
by scoring the latency of the stereotyped jumping from a circular
platform with a diameter of 35 cm placed 70 cm high. A cut-off time of
900 s was applied. Meanwhile, body temperature and weight of the
animals were measured before naloxone treatment, 15min, 30min and
60min after.
Finally, the effect of KP-13 on mechanical sensitivity was measured
30, 60 and 120min after peptide administration in male mice.
All responses were recorded by an investigator blinded to treat-
ments.
2.6. Statistical analysis
Data is presented as means ± SEM. Statistical analysis of the results
was performed by analysis of variance (ANOVA). For the effect of KP-13
on thermal nociceptive sensitivity in male and female mice, a three-way
mixed ANOVA was performed using between-subjects factors treatment
and sex and within-subject factor time. For multiple comparisons, the
Bonferoni post hoc test was used. In the case of the tail-flick tests with
antagonist and morphine treatments, two-factor ANOVA was done
(between-subject factors: KP-13 treatment and antagonist or morphine
treatment), followed by the Bonferoni post hoc test. For the analysis of
jumping latency in the acute withdrawal study, one-way ANOVA was
employed, followed by the Holm-Sidak post hoc test for multiple
comparisons. For the analysis of the PWTs two-way mixed ANOVA was
done, followed by the Bonferoni post hoc test. When the test of the
homogeneity of variances was not satisfied, nonparametric ANOVA on
ranks (Kruskal-Wallis) was performed, followed by Dunn’s test for
multiple comparisons. For the evaluation of the tail-flick, weight and
temperature recordings with combined treatments, two-way ANOVA
was performed, followed by the Bonferoni test for multiple compar-
isons. A probability level of less then 0.05 was accepted as indicating a
statistically significant difference.
3. Results
3.1. Effect of KP-13 on tail-flick latency
A three-way mixed ANOVA was conducted to examine the effect of
sex, time, and KP-13 treatment on nociceptive threshold of the animals
(Fig. 1). There was a statistically significant main effect for the treat-
ment factor [F(3,77)= 10.603, p < 0.001]. However, no significant
main effect for the sex factor was observed [F(1,77)= 0.179,
p=0.674] and no statistically significant interaction between the ef-
fect of KP-13 treatment and sexes [F(3,77)= 0.304, p=0.823]. In case
of the within-subject factor time, Mauchly’s test indicated that the as-
sumption of sphericity had been violated; therefore degrees of freedom
were corrected using the Huynh-Feldt estimates of sphericity. The re-
sults show that there was a significant main effect for time [F
(1.94,77)= 3.292, p=0.042]. No significant interaction was found
between the factors time and the treatment factor [F(5.81,77)= 1.798,
p=0.106]. Overall, kisspeptin induced a significant decrease in noci-
ceptive threshold, and the effect of the different levels of KP-13 treat-
ment did not depend on what level of sex or time is present (Fig. 1). As
kisspeptin’s effect on nociception did not differ among sexes, the rest of
the experiments were preformed with male mice.
3.2. Effect of KP-234 on KP-13 induced pronociception
The two-factor ANOVA revealed a statistically significant interac-
tion between the effect of KP-13 treatment and the effect of antagonist
treatment at 30min [F(1,27)= 12.586, p < 0.01], 60min [F(1,
27)= 22.860, p < 0.001] and 120min [F(1,27)= 22.955,
p < 0.001] (Fig. 2). No significant main effect was detected for the
antagonist factor [F(1,27)= 2.415, p= 0.133 at 30min; F
(1,27)= 1.306, p= 0.264 at 60min; F(1,27)= 0.554, p=0.465 at
120min]; however, a statistically significant main effect was found for
Fig. 1. The effect of KP-13 on pain sensitivity in the tail-flick test 30min after
treatment (A.), 60min after treatment (B.) and 120min after treatment (C.).
Mean and SEM are expressed. Numbers in parenthesis denote the number of
animals used. * p < 0.05 vs. control.
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the KP-13 treatment factor at all time points [F(1,27)= 15.498,
p < 0.01 at 30min; F(1,27)= 9.029, p < 0.01 at 60min; F
(2,27)= 13.611, p < 0.01 at 120min]. Based on these results, the
effect of KP-13 treatment depends on the presence of the antagonist.
KP-234 was able to prevent KP-13′s effect on nociception. The 0.1 μg of
KP-234 per se did not affect tail-flick latency (Fig. 2).
3.3. Effect of KP-13 on challenge dose of morphine
A two-factor ANOVA was conducted to analyze the effect of mor-
phine and KP-13 treatments on nociceptive threshold of the animals 30,
60 min after morphine injections (Fig. 3). There was a statistically
significant main effect for KP-13 treatment factor at 30min [F
(1,25)= 51.025, p < 0.0001] and 60min [F(1,25)= 10.458,
p=0.004]. Significant main effect for the morphine treatment factor
was also observed [F(1,25)= 217.226, p < 0.0001 for 30min; F
(1,25)= 28.630, p < 0.0001 for 60min) and a statistically significant
interaction between the two factors [F(1,25)= 26.210, p < 0.0001 for
30min; F(1,25)= 5.930, p= 0.023 for 60min]. A single dose of
2.4 mg/kg sc morphine induced an appr. 80% antinociception; 1 μg
dose of KP-13 significantly lowered the antinociceptive effect of mor-
phine 30 and 60min after the narcotic challenge (Fig. 3).
3.4. Effect of KP-13 on acute morphine tolerance
The two-way ANOVA on acute morphine tolerance showed a sig-
nificant main effect for the KP-13 treatment factor [F(1,24)= 25.563,
p < 0.001] 30min after the morphine challenge, a significant main
effect for the morphine tolerant factor [F(1,24)= 268.053, p < 0.001]
and a significant interaction between the two factors [F
(1,24)= 42.735, p < 0.001]. Thus, the effect of different levels of KP-
13 treatment does depend on which level of morphine tolerance is
present (Fig. 4). Acute tolerance was observed 24 h after a tolerance
inducing dose of morphine was applied sc. Our results showed that KP-
13 treatment 30min before tolerance induction prevents the develop-
ment of acute morphine tolerance. The KP-13-treated animals that re-
ceived the tolerance inducing dose of morphine showed a significantly
higher antinociceptive effect than tolerant animals both 30min [F
(3,22)= 78.333, p < 0.05], 60min [F(3,22)= 28.853, p < 0.05]
and 120min [F(3,22)= 13.188, p < 0.05] after injection of the 4mg/
kg sc test dose of morphine (Fig. 4).
3.5. Effect of KP-13 on naloxone-precipitated acute morphine withdrawal
In the naloxone-precipitated withdrawal studies KP-13 caused a
marked decrease in the jumping latency [F(3,39)= 19.995, p=0.008]
(Fig. 5) of animals from the platform.
The two-factor analysis of variance on weight changes revealed a
significant main effect for the treatments factor [F(3,118)= 36.746,
p < 0.001] and a significant main effect for the time factor [F
(2,118)= 7.445, p < 0.001]; however, the interaction between treat-
ments and time was not significant [F(6,118)= 0.245, p= 0.96], so
the effect of different levels of treatments does not depend on which
level of time is present (Fig. 6). The two-way ANOVA on body tem-
perature changes yielded a significant main effect for the treatments
factor [F(3,118)= 140.576, p < 0.001] and a significant main effect
for the time factor [F(2,118)= 45.568, p < 0.001]; however, the in-
teraction between treatments and time was not significant [F
(6,118)= 1.431, p= 0.209]. The effect of different levels of treatments
does not depend on what level of time is present. Morphine tolerant
Fig. 2. The effect of KP-234 on KP-13-induced pronociceptive action. Mean and
SEM are expressed. Numbers in parenthesis denote the number of animals used.
* p < 0.05 vs. control, +p < 0.05.
Fig. 3. The effect of KP-13 on morphine-induced antinociception in the tail-
flick test. Mean and SEM are expressed. Numbers in parenthesis denote the
number of animals used. * p < 0.05 vs. control. +p < 0.05.
Fig. 4. The effect of KP-13 on acute morphine tolerance in the tail-flick test.
Mean and SEM are expressed. Numbers in parenthesis denote the number of
animals used. * p < 0.05 vs. control. +p < 0.05.
Fig. 5. The effect of KP-13 on jumping behavior in naloxone-precipitated
morphine withdrawal. Mean and SEM are expressed. Numbers in parenthesis
denote the number of animals used. * p < 0.05 vs. control. +p < 0.05.
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mice showed a significant reduction in both weight (data not shown)
and temperature (Fig. 6) within the different levels of time (15min,
30 min and 60min) [p < 0.001]. The KP-13-treated morphine tolerant
group did not differ significantly from the morphine tolerant group.
Only a slight tendency for KP-13 to further reduce the weight loss and
hypothermia was observed. Of note is the result that KP-13 alone
caused a marked elevation in body temperature compared to the con-
trol animals within all levels of time [p < 0.001] (Fig. 6).
3.6. Effect of KP-13 on PWTs
A two-way mixed ANOVA was conducted to analyze the effect of
KP-13 (1 μg) on PWTs 30, 60 and 120min after peptide injections
(Fig. 7). In case of the within-subject factor time, Mauchly’s test in-
dicated that the assumption of sphericity had been violated; therefore
degrees of freedom were corrected using the Huynh-Feldt estimates of
sphericity. There was a statistically significant main effect for the KP-13
treatment factor [F(1,9)= 21.27, p=0.0013]. On the other hand, the
time factor and the interaction between factors treatment and time
were not significant [F(3,27)= 1.561, p= 0.221; F(3,27)= 0.626,
p=0.604]. 1 μg dose of KP-13 significantly lowered the mechanical
sensitivity 60min after the peptide treatment (Fig. 7).
4. Discussion
Central administration of KP-13 to CFLP mice causes a marked
pronociception in the tail-flick test. This is in accordance with previous
findings in hot plate and formalin tests conducted by Spampinato et al.
[46] and more recent results that of Elhabazi et al. [10]. In our ex-
periments, no linear dose-response curve, but rather an inverted bell-
shaped response was observed, which is well known in the literature,
and has already been described in the case of other neuropeptides [3].
Based on our results, there was no significant difference in KP-13′s
action on nociceptive sensitivity among the sexes. Both males and fe-
males exhibited similar pronociceptive phenotype in any given time
point. Sex differences in pain sensitivity as well as the over-
representation of characteristic pain syndromes in women point toward
the involvement of the reproductive system in pain modulation [1,35].
Clearly, there is a connection between the HPG axis and the regulation
of pain sensation; however, the underlying mechanism is not well un-
derstood and many of the published studies reported contradictory
results [32]. Kisspeptin might provide a link between the reproductive
and pain modulatory systems; however, our results suggest that kis-
speptin is not involved in mediating the sex differences in the pain
system. At the same time, pain threshold and tolerance varies over the
menstrual cycle, therefore it is possible that the reason for not detecting
any differences in KP-13′s action between the sexes is due to not taking
into consideration the cycle stage of the animals. As responsiveness to
KP-13 does not seem to be sex-dependent, the experiments performed
after the dose-response study were conducted in male mice only.
The effect of KP-13 on nociceptive sensitivity may be mediated
through its cognate receptor, KISS1R, or the NPFFRs receptors. In
support of KISS1R mediation stand several results. First, kisspeptin and
KISS1R are expressed in neuronal structures involved in nociception
signaling such as dorsal root ganglia and the dorsal horn lamina I and II
of the spinal cord as well as brain regions such as hippocampus,
amygdala, and periaqueductal grey [15,29]. This pattern of expression
suggests a function in pain modulation. Second, in the chronic in-
flammatory pain model, kisspeptin and KISS1R up-regulation was de-
tected at the level of the dorsal root ganglia and dorsal horn neurons
[29]. Third, Spampinato et al. reported that the KISS1R antagonist, KP-
234 exhibits a clearly analgesic effect in formalin test [46]. Fourth, the
NPFFR agonist, NPFF in numerous studies caused analgesia when the
route of administration was intrathecal instead of icv. [36]. Based on
the fact that kisspeptin also lowered nociceptive sensitivity in the case
of intrathecal and intraplantar injections, it is plausible that the effect of
kisspeptin is mediated by the KISS1R and not by the NPFFRs. In point of
fact, in our experiments KP-234, a KISS1R antagonist, blocked the
pronociceptive action of KP-13 suggesting that indeed KISS1R media-
tion is involved in KP-13′s effects on nociception. However, in the face
of the above mentioned data, Elhabazi et al. in a publication reported
that RF9 suppressed the hyperalgesic, and anti-morphine activity of icv.
administered kisspeptin [10]. In this study, the route of administration
compared to the study conducted by Spampinato et al. differed as an-
imals received kisspeptin icv. and not peripherally. Additionally, re-
ceptor binding data and two different functional assays provide further
support, in which all RF-amide peptides were found to target NPFF1R
and NPFF2R in a nanomolar concentration range [10]. Furthermore,
both NPFF1R and NPFF2R have been previously indicated in the
modulation of pain [18]. Hence, these results indicate NPFFR in-
volvement, at least, in the central kisspeptin actions rather then KISS1R
mediation. It must be noted that recent publications raise the possibility
that RF9 might not be a true selective antagonist of NPFF receptors as it
was unable to reverse the anorectic effect of a NPFF analogue and it
alone displayed an anorectic effect as well [25]. Plus, it might be a
KISS1R agonist in vitro and in vivo as well [30]. Furthermore, it must
be noted that Elhabazi et al. administered 3 nmol of kisspeptin-10 icv,
whereas in our experiment as well as that of Spampinato et al. no more
then 1 nmol was injected. It is possible that smaller concentrations of
kisspeptin act via KISS1R, while higher concentrations might also bind
NPFFRs. Undoubtably, results from these studies have been incon-
clusive. Still, in our experiments KP-234 prevented KP-13′s pronoci-
ceptive action which supports KISS1R mediation.
The activation of KISS1R results in calcium mobilization and re-
cruitment of Mitogen-activated protein kinases (MAPKs) such as the
extracellular signal-regulated kinases (ERK) and p38 [4]. Both ERK and
p38 contribute to central pain sensitization via post-translational and
Fig. 6. The effect of KP-13 on the hypothermia induced by naloxone-pre-
cipitated morphine withdrawal. Mean and SEM are expressed. Numbers in
parenthesis denote the number of animals used. * p < 0.05 vs. control.
Fig. 7. The effect of KP-13 on the paw withdrawal thresholds. Mean and SEM
are expressed. Numbers in parenthesis denote the number of animals used. *
p < 0.05 vs. control.
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transcriptional mechanisms [14]. As kisspeptins are potent stimulators
of ERK1/2 and p38, it is plausible that they induce increased nocicep-
tive sensitivity by affecting glutamate transmission[44], opioid [48]
and/or other neuropeptide signaling [22] in the spinal cord dorsal horn
neurons or upper brain regions implicated in nociceptive regulation.
The present results revealed an interaction between centrally in-
jected kisspeptin and morphine. KP-13 showed a clear anti-morphine
activity as it blunted the antinociceptive effect of a single injection of
morphine. This result is in concert with previous publications in which
KP-10 reversed morphine antinociception as well, the effect of which
have been blocked by RF9 [10]. Furthermore, in our experiments KP-13
inhibited the development of acute tolerance to morphine. Short-term
tolerance, an exposure to morphine up to 1 day, can be due to multiple
adaptive mechanisms that regulate μ opioid receptor (MOR) trafficking
to the cell surface [49] and/or counter adaptive mechanisms engaging
opposing or compensatory regulatory systems. One proposed is the RF-
amide family that might also contribute to the development of toler-
ance [12]. As kisspeptin has been previously demonstrated to bind and
activate NPFF receptors [23], it is plausible that its effect on acute
morphine tolerance is mediated by the NPFF system. Results of several
experiments suggest that NPFF might play a role in morphine tolerance
and dependence. First, antibodies against the peptide can reverse
morphine tolerance [17]. Second, NPFF was found to induce with-
drawal-like symptoms [26]. Last, more recent publications have re-
ported that the tolerance inducing effect of NPFF might be mediated by
GRK2-dependent phosphorylation of MOR induced by NPFF receptor
activation in cell cultures, which will ultimately lead to a decrease in
the number of functional MOR with no associated internalization of the
receptors [33]. Based on the above mentioned data, NPFF receptors
induce tolerance rather then inhibit it, which is in contrast with our
results with KP-13. This discrepancy might be explained by the differ-
ence in treatment protocols used in previous publications with NPFF
compared to our experiments. In other studies, NPFF was co-adminis-
tered with morphine; however, in our study, the animals received kis-
speptin 60min before morphine treatment. It is possible that KP-13
already reduced the number of functional MORs on the cell surface by
the time of morphine treatment, thus blunting the tolerance-inducing
effect of morphine [40]. Another possible reason behind our results
might be that the tolerance-inhibiting action of KP-13 was mediated not
by NPFFRs but KISS1R. This is supported by the distribution data of
KISS1R expression and the diverse signal transduction cascades mobi-
lized in case of receptor activation [4,15].
Our results also demonstrate that KP-13 aggravates naloxone-pre-
cipitated abstinence syndrome. It must be noted that a significant
change was only detected in escape behavior (jumping latency).
Significant change in temperature and weight between the morphine
withdrawal and the KP-13 treated morphine withdrawal groups was not
found, rather, only a tendency was observed. As previously mentioned,
the NPFF system as an opioid-modulating system involved in main-
taining homeostasis counteracts the action of opioids contributing
possibly to the development of tolerance [12]. In withdrawal studies,
NPFF was able to produce some signs of a withdrawal syndrome in
morphine-dependent rats [26]. Furthermore, the immunoneutralization
of NPFF or injection of antisense oligonucleotides to the precursor
proNPFFA decreased the intensity of withdrawal signs in morphine-
tolerant animals [11,17,27]. This suggests that NPFF system might play
a role in the mediation of the withdrawal syndrome. Taking these data
into consideration, it is possible that the effect of KP-13 on withdrawal
is mediated by the NPFF system.
Another interesting observation of our experiments was that KP-13
induced a hyperthermia in the animals revealed by the temperature
recordings in the acute withdrawal study. 1 μg of KP-13 caused a
marked elevation of body temperature 15, 30 and 60min after peptide
treatment compared to control mice. This underlies our previous results
in rats, in which both 1 μg and 2 μg of KP-13 induced a lasting (appr. 6 h
long) hyperthermia [7]. Thus, it seems that the hyperthermic action of
KP-13 is shared among the two species. This might be due to KP-13′s
direct effect on the thermoregulatory center in the hypothalamus and/
or on cardiovascular control and/or on metabolic rate. It has been
previously implicated by Rance et al. that the KNDy (kisspeptin, neu-
rokinin B and dynorphin) neurons of the arcuate nucleus send projec-
tions to the preoptic area where the thermoregulatory center is found
[39]. They propose that these neurons acting via the neurokinin 3 re-
ceptor (NK3R) might mediate a peripheral vasodilation [39]. This is
also supported by an article by Mittelman-Smith, which shows that the
ablation of neurokinin-3 expressing neurons (KNDy neurons) results in
a decreased tail skin temperature [31]. These results suggest that these
neurons mediate peripheral vasodilation; however, via neurokinin-3/
NK3R, not via kisspeptin/KISS1R signaling. Still, it is possible that KP-
13 increases the set-point of the thermoregulatory center. Literature
data also shows that kisspeptins might have a role in cardiovascular
control, namely a positive inotropic and vasoconstrictor effect. How-
ever, it must be noted that these seem to be peripheral rather then
central effects [24,28,41]. Considering the fact that we administered
KP-13 icv, it is possible, but rather unlikely, that it would reach a
plasma concentration high enough to act on the heart and vasculature.
Finally, kisspeptin might influence basic metabolism. In point of fact,
Tolson and colleagues found that in Kiss1r knock-out mice the body
weight, leptin level and adiposity increased. Furthermore, these mice
developed glucose intolerance and a decrease in appetite [47]. Overall,
it is not clear how KP-13 exerts its hyperthermic action. Nevertheless, it
must be noted that due to the increased core temperature, it is possible
that tail skin temperature might increase as well, which could influence
thermal nociception. Hole and Tjolsen proposed that an increased tail
skin temperature might lower the threshold in heat-radiant tail-flick
measurements [13]. Therefore, it is possible that the pronociceptive
effect of KP-13 is due to an increased tail temperature rather than to
altered nociception. However, in our experiments the tail skin of the
mice was preheated to 36 °C, and only after that was the noxious
thermal stimulus applied and the tail-flick latency measured. Thus, the
differences in tail skin temperatures were accounted for in the experi-
ment. Second, Lichtman et al. found that a 2 °C increase in tail tem-
perature did not cause a significant change in nociceptive threshold. In
our experiments the rise in core temperature did not exceed the 2 °C
[21]. Third, the skin-tail temperature might not have increased with the
core temperature in case of KP-13 acting via the thermoregulatory
center or the circulation. These, taken together, all suggest that KP-13
exerts a pronociceptive effect that is not due to any change in tail skin
temperature. To further characterize the pronociceptive effect of KP-13,
we also investigated KP-13′s effect on mechanical nociception and
found that icv. administration of KP-13 produced a marked increase in
sensitivity to non-noxious mechanical stimuli. This further supports the
contention that KP-13 indeed has an effect on nociception.
In conclusion, our results indicate that centrally injected KP-13 re-
duces the nociceptive threshold independent of the sex of CFLP mice in
the tail-flick test possibly through KISS1R activation, reverses morphine
antinociception, and reduces acute morphine tolerance. Furthermore,
KP-13 seems to worsen the withdrawal signs precipitated by naloxone
in adult mice. Our data confirms and provides further support to the
concept that all RF-amide peptides might play a modulatory role in
nociception and raises the idea that with their diverse neuroendocrine
functions might be important for the integration of neuroendocrine and
nociceptive processes. In point of fact, several lines of evidence suggest
an interaction between the reproductive axis and pain sensitivity,
therefore kisspeptin might be an additional factor relaying information
about reproductive state to nociceptive centers.
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